If youre in Louisiana, look into clinics like Mochi Health that serve all 50 states
Increasing the number of intestinal endocrine L-cells According to the impairment of L-cells development in T2DM, a promising strategy for treating T2DM is to increase the number of L-cells in the intestine, thereby increasing the production of GLP-1
161 The trials involved adult participants with T2DM aged 18 to 75, conducted across 42 research and medical centers in the United States
But if US pharma giants are focused on building impenetrable thickets around every successful drug class, how can smaller players co-own, license, or even innovate in the periphery without facing immediate litigation
Ongoing trials are evaluating their potential benefits in populations with type 2 diabetes mellitus and either CKD or MASLD [101,102]
Proc Natl Acad Sci 79(2):345349 Ma Y, Huang Y, Yan L, Gao M, Liu D (2013) Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance